Company: Bicycle Therapeutics
Job title: Director – In Vivo Pharmacology
Johanna Lahdenranta, PhD, Director, in vivo pharmacology. Johanna joined Bicycle in 2018 and has been overseeing pre-clinical in vivo pharmacology work across Bicycle programs from Bicycle toxin conjugates to tumor-targeted immune cell agonists. She has 10+ years of industry experience and has previously worked on the in vivo pharmacology from large biologics to small molecules at Merrimack Pharmaceuticals and Forma Therapeutics. She obtained her PhD from University of Helsinki and did her pre-doctoral and postdoctoral training at MD Anderson Cancer Center and Massachusetts General Hospital.
Discussion/Q&A 10:20 am
day: Day One
Fully Synthetic Tumor-Targeted Immune Cell Agonists (TICAs) Induce Anti-Cancer Immunity Through Tumor Localized CD137 Agonism 9:30 am
We have developed tumor-targeted immune cell agonists (TICAs™) based on constrained bicyclic peptides (Bicycles®) by linking Bicycles against costimulatory receptors (e.g. CD137) to those against tumor antigens (e.g. EphA2) creating potent agonists that activate costimulatory receptors selectively in the presence of tumor cells Humanized (huPBMC) tumor xenograft models, as well as transgenic huCD137 syngeneic mouse…Read more
day: Day One